Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Common Equity: 2021-2022

Historic Common Equity for Cardiol Therapeutics (CRDL) over the last 1 years, with Sep 2022 value amounting to $45.0 million.

  • Cardiol Therapeutics' Common Equity rose 94.72% to $45.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $45.0 million, marking a year-over-year increase of 94.72%. This contributed to the annual value of $60.8 million for FY2021, which is N/A change from last year.
  • According to the latest figures from Q3 2022, Cardiol Therapeutics' Common Equity is $45.0 million, which was down 8.74% from $49.3 million recorded in Q2 2022.
  • Cardiol Therapeutics' Common Equity's 5-year high stood at $60.5 million during Q4 2021, with a 5-year trough of $23.1 million in Q3 2021.
  • Its 2-year average for Common Equity is $46.5 million, with a median of $49.3 million in 2022.
  • Data for Cardiol Therapeutics' Common Equity shows a peak YoY surged of 94.72% (in 2022) over the last 5 years.
  • Cardiol Therapeutics' Common Equity (Quarterly) stood at $60.5 million in 2021, then soared by 94.72% to $45.0 million in 2022.
  • Its Common Equity stands at $45.0 million for Q3 2022, versus $49.3 million for Q2 2022 and $54.6 million for Q1 2022.